TW201642865A - ４－（４－氟－２－甲氧苯基）－ｎ－｛３－［（ｓ－甲基磺醯亞胺醯基）甲基］苯基｝－１，３，５－三－２－胺於治療胃癌之用途 - Google Patents

４－（４－氟－２－甲氧苯基）－ｎ－｛３－［（ｓ－甲基磺醯亞胺醯基）甲基］苯基｝－１，３，５－三－２－胺於治療胃癌之用途 Download PDF

Info

Publication number
TW201642865A
TW201642865A TW105109282A TW105109282A TW201642865A TW 201642865 A TW201642865 A TW 201642865A TW 105109282 A TW105109282 A TW 105109282A TW 105109282 A TW105109282 A TW 105109282A TW 201642865 A TW201642865 A TW 201642865A
Authority
TW
Taiwan
Prior art keywords
myc
amplification
fluoro
methoxyphenyl
methyl
Prior art date
Application number
TW105109282A
Other languages
English (en)
Chinese (zh)
Inventor
阿恩 舒爾茨
Original Assignee
拜耳製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 拜耳製藥公司 filed Critical 拜耳製藥公司
Publication of TW201642865A publication Critical patent/TW201642865A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
TW105109282A 2015-03-24 2016-03-24 ４－（４－氟－２－甲氧苯基）－ｎ－｛３－［（ｓ－甲基磺醯亞胺醯基）甲基］苯基｝－１，３，５－三－２－胺於治療胃癌之用途 TW201642865A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15160587 2015-03-24

Publications (1)

Publication Number Publication Date
TW201642865A true TW201642865A (zh) 2016-12-16

Family

ID=52779521

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105109282A TW201642865A (zh) 2015-03-24 2016-03-24 ４－（４－氟－２－甲氧苯基）－ｎ－｛３－［（ｓ－甲基磺醯亞胺醯基）甲基］苯基｝－１，３，５－三－２－胺於治療胃癌之用途

Country Status (2)

Country Link
TW (1) TW201642865A (fr)
WO (1) WO2016150902A1 (fr)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2003037346A1 (fr) 2001-10-31 2003-05-08 Cell Therapeutics, Inc. Derives de 6-phenyl-n-phenyl-(1,3,5)-triazine-2,4-diamine et composes apparentes ayant un effet inhibiteur de l'acide lysophosphatidique acyltransferase beta (lpaat-beta) et destines a etre utilises pour traiter le cancer
EP2256108B1 (fr) 2002-07-18 2016-03-23 Janssen Pharmaceutica NV Inhibiteurs des kinases a base de triazine substituee
JP2006518381A (ja) 2003-02-07 2006-08-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
JP4305477B2 (ja) 2006-07-25 2009-07-29 トヨタ自動車株式会社 火花点火式内燃機関
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
CN101568529A (zh) 2006-12-22 2009-10-28 诺瓦提斯公司 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008129080A1 (fr) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibiteurs de protéine kinases
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
JP5693951B2 (ja) 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
JP5611826B2 (ja) 2007-09-04 2014-10-22 ザ スクリプス リサーチ インスティテュート タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
EP2488503A1 (fr) 2009-10-12 2012-08-22 Myrexis, Inc. Composés d'amino-pyrimidine en tant qu'inhibiteurs de tbkl et ou d'ikk epsilon
EP2527332A1 (fr) * 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phényl-1,3,5-triazin-2-amines portant un groupe sulfoximine en tant qu'inhibiteurs de CDK9
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺

Also Published As

Publication number Publication date
WO2016150902A1 (fr) 2016-09-29

Similar Documents

Publication Publication Date Title
EP3849558B1 (fr) Dérivés de thiocarbamate en tant qu'inhibiteurs d'a2a, composition pharmaceutique associée et combinaisons avec des agents anticancéreux
TWI689307B (zh) 經取代之2,3-二氫咪唑并[1,2-c]喹唑啉之用途
CN107683138A (zh) 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途
KR102764122B1 (ko) 미만성 거대 b-세포 림프종을 치료하기 위한 5-플루오로-4-(4-플루오로-2-메톡시페닐)-n-[4-[(s-메틸술폰이미도일)메틸]피리딘-2-일]피리딘-2-아민의 용도
TW201625261A (zh) ４－（４－氟－２－甲氧苯基）－ｎ－｛３－［（ｓ－甲磺醯亞胺醯基）甲基］苯基｝－１，３，５－三－２－胺於治療白血病之用途
TW201642865A (zh) ４－（４－氟－２－甲氧苯基）－ｎ－｛３－［（ｓ－甲基磺醯亞胺醯基）甲基］苯基｝－１，３，５－三－２－胺於治療胃癌之用途
TW201642866A (zh) ４－（４－氟－２－甲氧苯基）－ｎ－｛３－［（ｓ－甲基磺醯亞胺醯基）甲基］苯基｝－１，３，５－三－２－胺於治療淋巴癌之用途
TW201642867A (zh) ４－（４－氟－２－甲氧基苯基）－ｎ－｛３－［（ｓ－甲基磺醯亞胺醯基）甲基］苯基｝－１，３，５－三□－２－胺於治療多發性骨髓瘤之用途
HK40029614A (en) Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma
CA2904149A1 (fr) Utilisation de (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide pour le traitement de tumeurs specifiques